Enhanced evidence collection methodologies can improve approval rates and ensure reimbursement. Pharma companies should build an internal, cross-functional evidence team responsible for investigating new ways to collect and report clinical trial data

Post pandemic, pharma and regulators are both working to accelerate the transformative power of electronic filing 

The FDA and other regulatory bodies are increasingly willing to accept real-world evidence as part of approvals. Pharma is up to the task

Patient real-world data contains a wealth of potentially valuable information for life sciences commercial teams, if they can filter out the noise